Abstract
A case story is presented, describing a 46 y old man, with a relapsing hairy cell leukaemia. After treatment with monoclonal anti CD-20 antibodies (rituximab) 375 mg/week, four times, a complete remission was obtained which has lasted >9 months. The rituximab treatment produced a better remission than earlier treatments with alpha-interferon and chlorodeoxyadenosine. In addition, in contrast to other treatments, no initial worsening of the pancytopenia was observed.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Cheson BDet al. Treatment of hairy cell leukemia with 2 chlorodeoxyadenosine via the group C protocol mechanism of the National Cancer Institute: A report of 979 patients.J Clin Oncol 1998;16: 3007–3015.
McLaughlin Pet al.. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of the patients respond to a four-dose treatment program.J Clin Oncol 1998;16: 2825–2833.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hagberg, H. Chimeric monoclonal anti-CD20 antibody (rituximab)—an effective treatment for a patient with relapsing hairy cell leukaemia. Med Oncol 16, 221–222 (1999). https://doi.org/10.1007/BF02906136
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02906136